A randomized, controlled, multidose, multicenter, adaptive phase II/III study in infants with proliferating infantile hemangiomas requiring systemic therapy to compare four regimens of propranolol (1 or 3 mg/kg/day for 3 or 6 months) to placebo

HS 2009-7210, e-MOD 9178
Hemangioma, Pediatric
Jennifer Soung, MD
843 Health Sciences Road Hewitt Hall Room 1001 UC Irvine
To evaluate a new drug for infantile hemangiomas
Infants age 35 to 150 days old who have facial hemangiomas
The study is 96 weeks long. There are a total of 14 visits during the 96-week period. Some of the visits will take between 1 to 2 hours while other visits will take longer (4 to 6 hours).
The patient may have improvement in the size of their hemangioma
Patient's parent/legal guardian will not be compensated for their child's participation in this study; their child will receive a brown toy bear for participating in this study. However the parent/legal guardian will be refunded for travel expenses they incur during their child's participation in this study such as parking.
Brian Swasdibutra, Department of Dermatology